FDANews

ORIGENIS AND ALCON EXTEND RESEARCH ALLIANCE

Germany-based Origenis GmbH has announced that it has extended the research alliance with Alcon Research to develop small molecule drugs against important ophthalmic targets for two years. The alliance combines Origenis' compound design and synthesis capabilities with Alcon's applied biology expertise, screening capabilities and development expertise.

Under the terms of the agreement, Alcon will retain the rights to any products for ophthalmic and nasal applications, and Origenis will retain certain rights to all other uses of drug candidates discovered during the alliance.